Raymond James Financial
SYRE icon

Raymond James Financial’s Spyre Therapeutics SYRE Stock Holding History

Raymond James Financial’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.76M Buy
53,627
+33,872
+171% +$2.47M ﹤0.01% 2770
2026
Q1 		$996K Buy
+19,755
New +$745K ﹤0.01% 3842
2025
Q3 		– Sell
-16
Closed -$240 – 6578
2025
Q2 		$240 Buy
+16
New +$237 ﹤0.01% 6760

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Raymond James Financial's SYRE Position: Q2 2026 in Review

Raymond James Financial increased its Spyre Therapeutics (SYRE) stake by 171% in Q2 2026, buying an estimated $2.47M and bringing the position to 53,627 shares worth $4.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2770.

Raymond James Financial first reported a position in SYRE in Q2 2025 and has held it in 3 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Raymond James Financial held 53,627 shares of Spyre Therapeutics worth $4.76M as of Q2 2026.
  • Raymond James Financial bought 33,872 Spyre Therapeutics shares in Q2 2026, an estimated $2.47M.
  • Spyre Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2770 holding.
  • Raymond James Financial first reported a position in Spyre Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.